Entresto Tablet, Film Coated
Product Images NDC 71610-806

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Entresto (NDC 71610-806). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

71610-806-32 (71610 806 32)

71610-806-32 (71610 806 32)
This text appears to be a description of a medication called Sacubitril/Valsartan (Entresto), with references to NDC# 71610.606-32 and Batch:0. It seems to provide information related to prescription or dosage of the medication.*
FDA Label Image

Aphena (Aphena)

Aphena (Aphena)
FDA Label Image

Valsartan Structural Formula (Entresto 01)

Valsartan Structural Formula (Entresto 01)
FDA Label Image

Figure 1: Effect Of Entresto On Pharmacokinetics Of Coadministered Drugs (Entresto 02)

Figure 1: Effect Of Entresto On Pharmacokinetics Of Coadministered Drugs (Entresto 02)
This text provides information about the geometric mean ratio and 90% confidence interval of coadministered drugs such as Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil. It also indicates a change relative to reference.*
FDA Label Image

Figure 2: Pharmacokinetics Of Entresto In Specific Populations (Entresto 03)

Figure 2: Pharmacokinetics Of Entresto In Specific Populations (Entresto 03)
FDA Label Image

Figure 3: Kaplan-meier Curves For The Primary Composite Endpoint (a), Cardiovascular Death (b), And Heart Failure Hospitalization (c) (Entresto 04)

Figure 3: Kaplan-meier Curves For The Primary Composite Endpoint (a), Cardiovascular Death (b), And Heart Failure Hospitalization (c) (Entresto 04)
FDA Label Image

Figure 4: Primary Composite Endpoint (cv Death Or Hf Hospitalization) (Subgroup Analysis)

Figure 4: Primary Composite Endpoint (cv Death Or Hf Hospitalization) (Subgroup Analysis)
This information provides a detailed breakdown of demographic and clinical characteristics of a population, including age, gender, weight, race, region, medical conditions (e.g., heart failure, diabetes, hypertension), medications (ENTRESTO and Enalapril), and outcomes (Hazard Ratio). The data is organized in a table format showing percentages within each subgroup, helping to identify trends and patterns among different variables in the study population.*
FDA Label Image

Figure 5: Mean Number Of Events Over Time For The Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death (Entresto 09)

Figure 5: Mean Number Of Events Over Time For The Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death (Entresto 09)
FDA Label Image

Figure 6: Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death – Subgroup Analysis (paragon-hf) (Entresto 10)

Figure 6: Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death – Subgroup Analysis (paragon-hf) (Entresto 10)
FDA Label Image

Figure 7: Treatment Effect For The Composite Endpoint Of Time To First Hf Hospitalization Or Cv Death By Lvef In Paradigm-hf And Paragon-hf (Entresto 11)

Figure 7: Treatment Effect For The Composite Endpoint Of Time To First Hf Hospitalization Or Cv Death By Lvef In Paradigm-hf And Paragon-hf (Entresto 11)
This text provides a comparison of hazard ratios for the PARADIGM-HF and PARAGON-HF trials, specifically comparing ENTRESTO versus enalapril and ENTRESTO versus valsartan. It also displays left ventricular ejection fraction percentages at the screening stage.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.